- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Chronic Obstructive Pulmonary Disease (COPD) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market size is estimated to be worth US$ 13260 million in 2021 and is forecast to a readjusted size of USD 15960 million by 2028 with a CAGR of 2.7% during review period. Hospital accounting for % of the Chronic Obstructive Pulmonary Disease (COPD) Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Corticosteroids segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chronic Obstructive Pulmonary Disease (COPD) Treatment include AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline, Novartis AG, and Teva Pharmaceutical Industries, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Obstructive Pulmonary Disease (COPD) Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Bronchodilators
Others
Market segment by Application, can be divided into
Hospital
Clinic
Retail Pharmacies
Other
Market segment by players, this report covers
AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline
Novartis AG
Teva Pharmaceutical Industries
Sunovion Pharmaceuticals
CHIESI Farmaceutici
Orion Corporation
Mylan
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chronic Obstructive Pulmonary Disease (COPD) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chronic Obstructive Pulmonary Disease (COPD) Treatment, with revenue, gross margin and global market share of Chronic Obstructive Pulmonary Disease (COPD) Treatment from 2019 to 2022.
Chapter 3, the Chronic Obstructive Pulmonary Disease (COPD) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Obstructive Pulmonary Disease (COPD) Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chronic Obstructive Pulmonary Disease (COPD) Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Chronic Obstructive Pulmonary Disease (COPD) Treatment
1.2 Classification of Chronic Obstructive Pulmonary Disease (COPD) Treatment by Type
1.2.1 Overview: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Type in 2021
1.2.3 Corticosteroids
1.2.4 Phosphodiesterase Type 4 Inhibitors
1.2.5 Bronchodilators
1.2.6 Others
1.3 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Application
1.3.1 Overview: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Retail Pharmacies
1.3.5 Other
1.4 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size & Forecast
1.5 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Region
1.5.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region, (2017-2022)
1.5.3 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers
1.6.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints
1.6.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Boehringer Ingelheim International GmbH
2.2.1 Boehringer Ingelheim International GmbH Details
2.2.2 Boehringer Ingelheim International GmbH Major Business
2.2.3 Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.2.4 Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.3.4 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.4.4 Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 Teva Pharmaceutical Industries
2.5.1 Teva Pharmaceutical Industries Details
2.5.2 Teva Pharmaceutical Industries Major Business
2.5.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.5.4 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.6 Sunovion Pharmaceuticals
2.6.1 Sunovion Pharmaceuticals Details
2.6.2 Sunovion Pharmaceuticals Major Business
2.6.3 Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.6.4 Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Sunovion Pharmaceuticals Recent Developments and Future Plans
2.7 CHIESI Farmaceutici
2.7.1 CHIESI Farmaceutici Details
2.7.2 CHIESI Farmaceutici Major Business
2.7.3 CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.7.4 CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 CHIESI Farmaceutici Recent Developments and Future Plans
2.8 Orion Corporation
2.8.1 Orion Corporation Details
2.8.2 Orion Corporation Major Business
2.8.3 Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.8.4 Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Orion Corporation Recent Developments and Future Plans
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.9.4 Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Mylan Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Market Share in 2021
3.2.2 Top 10 Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Head Office, Products and Services Provided
3.4 Chronic Obstructive Pulmonary Disease (COPD) Treatment Mergers & Acquisitions
3.5 Chronic Obstructive Pulmonary Disease (COPD) Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2028)
6.2 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2028)
6.3 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
6.3.1 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2028)
6.3.2 United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2028)
7.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2028)
7.3 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
7.3.1 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2028)
7.3.2 Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
7.3.3 France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region
8.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Region (2017-2028)
8.3.2 China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
8.3.5 India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2028)
9.2 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2028)
9.3 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
9.3.1 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
10.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region (2023-2028)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 9. AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Boehringer Ingelheim International GmbH Corporate Information, Head Office, and Major Competitors
Table 11. Boehringer Ingelheim International GmbH Major Business
Table 12. Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 13. Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 17. GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 21. Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceutical Industries Major Business
Table 24. Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 25. Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Sunovion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Sunovion Pharmaceuticals Major Business
Table 28. Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 29. Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. CHIESI Farmaceutici Corporate Information, Head Office, and Major Competitors
Table 31. CHIESI Farmaceutici Major Business
Table 32. CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 33. CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Orion Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Orion Corporation Major Business
Table 36. Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 37. Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Mylan Corporate Information, Head Office, and Major Competitors
Table 39. Mylan Major Business
Table 40. Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 41. Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Chronic Obstructive Pulmonary Disease (COPD) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Head Office, Products and Services Provided
Table 46. Chronic Obstructive Pulmonary Disease (COPD) Treatment Mergers & Acquisitions in the Past Five Years
Table 47. Chronic Obstructive Pulmonary Disease (COPD) Treatment New Entrants and Expansion Plans
Table 48. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) by Type (2017-2022)
Table 49. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Type (2017-2022)
Table 50. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Forecast by Type (2023-2028)
Table 51. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2022)
Table 52. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Forecast by Application (2023-2028)
Table 53. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Picture
Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Type in 2021
Figure 3. Corticosteroids
Figure 4. Phosphodiesterase Type 4 Inhibitors
Figure 5. Bronchodilators
Figure 6. Others
Figure 7. Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Application in 2021
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Other Picture
Figure 12. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region (2017-2028)
Figure 15. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region in 2021
Figure 16. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers
Figure 22. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints
Figure 23. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends
Figure 24. AstraZeneca Recent Developments and Future Plans
Figure 25. Boehringer Ingelheim International GmbH Recent Developments and Future Plans
Figure 26. GlaxoSmithKline Recent Developments and Future Plans
Figure 27. Novartis AG Recent Developments and Future Plans
Figure 28. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 29. Sunovion Pharmaceuticals Recent Developments and Future Plans
Figure 30. CHIESI Farmaceutici Recent Developments and Future Plans
Figure 31. Orion Corporation Recent Developments and Future Plans
Figure 32. Mylan Recent Developments and Future Plans
Figure 33. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Players in 2021
Figure 34. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share in 2021
Figure 36. Global Top 10 Players Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Type in 2021
Figure 39. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share Forecast by Type (2023-2028)
Figure 40. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Application in 2021
Figure 41. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share Forecast by Application (2023-2028)
Figure 42. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2017-2028)
Figure 43. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2017-2028)
Figure 44. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2017-2028)
Figure 45. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2017-2028)
Figure 49. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2017-2028)
Figure 50. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2017-2028)
Figure 51. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region (2017-2028)
Figure 59. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2017-2028)
Figure 66. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2017-2028)
Figure 67. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
